Braveheart Bio
Transforming Hypertrophic Cardiomyopathy Care
Braveheart Bio is a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions. The company is backed by experienced life science investors including A…
B2B/B2B2C SaaS-esque biotech translational model (clinical development and potential partnerships/licensing)


